Kantar Health's oncology expert Stephanie Hawthorne is providing commentary on the most eye-catching trials presented at this year's ESMO congress in Copenhagen. Part one looks at new pivotal
US biotech Clovis Oncology has filed its ovarian cancer drug rucaparib with the US regulator – a crucial development as this is now the only drug left in the company's pipel
Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted.
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas
